Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 14/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343161 | 1.00 | SLC6A9 (0.68) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4328746 | 0.90 | SLC6A9 (0.68) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4328752 | 0.90 | SLC6A9 (0.68) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4335567 | 0.88 | SLC6A9 (0.72) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4335562 | 0.88 | SLC6A9 (0.72) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4336393 | 0.87 | SLC6A9 (0.80) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4336388 | 0.87 | SLC6A9 (0.80) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL4348210 | 0.83 | SLC6A9 (0.79) | SLC6A9SMN1; SMN2KDM4ELTA4H | |
| SCHEMBL4348216 | 0.83 | SLC6A9 (0.79) | SLC6A9SMN1; SMN2KDM4ELTA4H | |
| SCHEMBL10204257 | 0.82 | SLC6A9 (0.45) | SLC6A9SMN1; SMN2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | claimed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | claimed |
| EP-1622868-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096761-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | claimed |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-09-26 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| EP-1871165-B1 | METHOD OF TREATING SCHIZOPHRENIA PRODROME | UNIV YALE (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7612068-B2 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| US-20090215842-A1 | Method of Treating Schizophrenia Prodrome | YALE UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | H. LUNDBECK A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| EP-1622868-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096761-A1 | AROMATIC OXYPHENYL AND AROMATIC SULFANYLPHENYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | SLC6A9 58/4885SMN1; SMN2 3724/4885KDM4E 3772/4885 |
| US-20060235003-A1 | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives | TYR, TPST2, COMT | SLC6A9 2305/4885SMN1; SMN2 1849/4885KDM4E 1025/4885 |
| US-20190290632-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | SLC6A9 58/4885SMN1; SMN2 3724/4885KDM4E 3772/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | SLC6A9 23/4885SMN1; SMN2 3342/4885KDM4E 3317/4885 |
| US-20190290645-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | SLC6A9 189/4885SMN1; SMN2 3648/4885KDM4E 2901/4885 |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | SLC6A9 1796/4885SMN1; SMN2 3932/4885KDM4E 1221/4885 |
| US-20090215842-A1 | Method of Treating Schizophrenia Prodrome | SLC18A2, GRIN1, GRIA1 | SLC6A9 55/4885SMN1; SMN2 3330/4885KDM4E 4749/4885 |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | SLC6A9 233/4885SMN1; SMN2 3538/4885KDM4E 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.